CD274 and cancer: Previous studies have shown that treatment with low-dose THIO followed by anti-PD-1/PD-L1 immunotherapy eliminated advanced tumors in a clinical precursor cell model and generated cancer cell-specific immune memory, thus enabling the immune system to retain its activity against cancer cells after treatment cessation (Kodym et al., 2009).